This website uses cookies. By continuing you are agreeing to our privacy policy.

Anthony Faber, PhD

Research Awards Nationwide Recipient (2015-2016)

Virginia Commonwealth University
Resensitizing Cells to Lung Cancer Targeted Therapy
Lung Cancer Discovery Award
Funded by LUNG FORCE

Genetic variations and cell mutations contribute to the growth and development of cancer. Drugs called targeted therapies are designed for specific gene mutations in particular cancers. One effective targeted therapy is EGFR inhibitors, which target lung cancers with mutations in the EGFR gene. These mutations are often found in nonsmoking young patients. EGFR inhibitors are often effective for many of these patients but most eventually become resistant to the drugs. This can occur through a process in the cancer called epithelial-mesenchymal transition (EMT). We will screen for drug compounds that can reverse this effect in EMT cells and re-sensitize them to EGFR inhibitors.

Update: Cell studies have identified a mechanism of EMT-mediated resistance that is active in both EGFR-mutant lung cancers as well as KRAS-mutant lung cancers. Drug strategies to reverse this resistance have been identified, have shown to be effective and are being further tested.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.